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Abstract
The intestinal microbiome is essential for maintaining human health and defending against intestinal pathogens. Alterations of the intestinal
microbiota, also termed dysbiosis, play a pivotal role in the pathogenesis of various human diseases. Faecal microbiota transplantation (FMT)
is aimed at correcting these alterations by delivering faecal microorganisms from a healthy person to the intestines of a patient. At present,
recurrent Clostridium difﬁcile infection is the only indication supported by solid scientiﬁc evidence, but many ongoing studies are investigating
FMT in other dysbiosis-related diseases, such as inﬂammatory bowel disease. As there are no systematic methodological investigations,
several questions about techniques, donor screening and safety issues remain. This shortage of evidence, especially on long-term safety
concerns, is leading to worldwide controversy regarding the use of FMT. Regulations by healthcare authorities vary among different
countries. This review reﬂects the Austrian situation and its FMT guidelines concerning indications, techniques and donor screening,
recently developed by local scientiﬁc societies.
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Introduction
The intestinal microbiota has a pivotal role for the human
organism in the maintenance of health, especially for defence
against pathogenic microorganisms [1]. Speciﬁc alterations in
the intestinal microbiota, termed dysbiosis, seem to be
involved in the pathogenesis of a variety of intestinal and
extra-intestinal diseases, such as intestinal infections, inﬂam-
matory bowel disease (IBD), irritable bowel syndrome,
metabolic syndrome, and autoimmune diseases [2–9].
Although there is no generally accepted deﬁnition of dysbiosis,
most authors consider decreased microbial diversity or an
increased abundance of certain pathobionts or opportunistic
pathogens as intestinal dysbiosis [5,10–13]. Faecal microbiota
transplantation (FMT), also known as stool transplantation, is a
therapeutic procedure aimed at restoring the intestinal
microbiota by the administration of faecal microorganisms
from a healthy donor into the intestinal tract of a patient
[10,14–16]. The increasing numbers of reported Clostridium
difﬁcile infections (CDIs) since the millennium have resulted in
a distinct interest in therapeutic FMT in the medical commu-
nity, as this method is mainly used to treat recurrent CDI.
There is, however, much controversy regarding the use of
FMT among physicians, because of potential safety concerns.
FMT regulations produced by healthcare authorities vary from
very strict, such as those of the Food and Drug Administration
in the USA [17], to non-existent in most other countries. The
purpose of this review is to describe the situation in Austria,
especially with regard to local guidelines recently developed by
scientiﬁc societies.
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Guidelines and Regulation for FMT in Austria
The Austrian Federal Ofﬁce for Safety in Health Care, which
executes federal policy in areas of infectious disease control
and pharmaceuticals, sees FMT as a therapeutic intervention
that should not be considered a pharmaceutical drug and
therefore not be regulated by the Austrian Medicines Act.
FMT is also not subject to the Medical Devices Act or to the
Austrian Transplantation Act. To avoid a legally precarious
state for physicians who want to use FMT to treat their
patients, the Austrian Federal Ministry of Health was contacted
about developing national guidelines. The Austrian Federal
Ministry of Health saw no reason to act, and based the
decision on the current state of knowledge.
In order to prevent an unclear situation for physicians,
scientiﬁc societies in this ﬁeld decided to create a working
group of experts from the Austrian Society of Gastroenter-
ology and Hepatology in cooperation with the Austrian
Society of Infectious Disease and Tropical Medicine and the
Austrian Agency for Health and Food Safety to develop FMT
guidelines for Austria. This working group developed a
consensus report for the use of FMT in Austria that was
approved by both societies and is currently in the publication
process in the ofﬁcial organ of the Austrian Society of
Gastroenterology and Hepatology [18]. This consensus is
intended to provide instructions for physicians who want to
use FMT, including indications, methodology, and donor
screening, based on the current medical literature. The
guidelines further recommend that FMT may be used only
by physicians for certain indications and with safety precau-
tions. In our opinion, FMT ‘self-administration’ by patients, as
has been reported [19–21], or by alternative practitioners
should be avoided, owing to potential risks. The latter
situation would be the case if FMT were restricted too
rigorously by medical authorities.
So far in Austria, FMT has been mainly used by gastroente-
rologists working at departments of gastroenterology and
hepatology, including the university hospitals in Vienna, Graz,
and Innsbruck, as well as major non-university-associated
gastroenterology departments in Vienna, Carinthia, and Upper
Austria. We do not know whether FMT has been used in the
outpatient setting by practitioners in Austria so far.
Indications for FMT
CDI
FMT is most commonly used for recurrent forms of CDI.
There are currently many cohort studies in a large number of
patients and a randomized controlled trial showing a dramatic
effect of FMT for this indication [14,15,22–24]. Therefore,
FMT is recommended by international medical societies for
the treatment of recurrent CDI, on the basis of solid scientiﬁc
evidence. The European Society for Clinical Microbiology and
Infectious Diseases recommends the use of FMT in their
current CDI guidelines as preferable to vancomycin or
ﬁdaxomicin in patients with at least two CDI recurrences
(i.e. three CDI episodes in an single patient) [25]. Austrian
guidelines also recommend FMT to treat recurrent CDI, in
agreement with European Society for Clinical Microbiology
and Infectious Diseases guidelines, and further suggest FMT as
a treatment option for severe CDI as an alternative to total
colectomy, if standard therapy fails [18].
In Austria, the estimated number of CDI cases is
approximately 7000 per year [26]. Assuming a recurrence rate
of 20%, as reported in the literature [27], approximately 250–
300 patients with two recurrences (three episodes) of CDI
would need to be treated with FMT according to these
guidelines in Austria. If cases were evenly distributed, this would
mean that the current centres performing FMT would need to
treat 40–50 cases of recurrent CDI per year. So far, we are not
aware that these numbers of CDI patients are being treatedwith
FMT at any hospital in Austria. This suggests that physicians in
Austria still hesitate to choose FMT as an early treatment option
for recurrent CDI. Obviously, the current centres offering FMT
have sufﬁced so far for the numberof patients requiring this form
of therapy.
Other indications
Other potential indications for the use of FMT are the
treatment of inﬂammatory bowel diseases, especially ulcerative
colitis (UC). Studies using FMT for the treatment of UC have
been performed in Austria [28,29] and are still ongoing [30].
Whereas a single application of FMT, as is recommended for
patients with CDI, seems to be without major beneﬁt for UC
patients [28,29], a protocol using repeated FMT has shown a
clinical response in approximately 50% of patients [30].
Owing to a lack of sufﬁcient data at present, Austrian
guidelines only recommend the use of FMT to treat UC or
indications other than CDI in clinical studies with appropriate
safety measures.
Recommended Donor Screening in Austria
The selection of possible donors is one of the key points in
executing FMT. The deﬁnition of potentially transmittable
diseases in this context remains unclear. Because of a lack of
knowledge about the transferability of tumorigenesis or
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autoimmune, metabolic and neuropsychiatric diseases, the
long-term side effects are unknown. In principle, donors
genetically related to FMT recipients show similarities in their
intestinal microbiota [31]. Donors and recipients living in the
same household and/or in a sexual relationship are largely
exposed to the same infectious risk factors. Therefore, the
possibility of transmitting infectious agents via faeces from
related donors is assumed to be reduced. However, FMT has
also been successfully performed with donor faeces from
unrelated healthy volunteers [32]. The success rates of FMT
for recurrent CDI are comparable for related and unrelated
donors (89.5% vs. 90.7%) [33]. The appropriateness or advan-
tage of donor faeces in terms of relationship status for
indications other than CDI (e.g. UC and metabolic syndrome)
remains uncertain.
There are different screening procedures for donors.
Recommendations about the parameters to be tested for
donor screening are inconsistent among various institutions
and countries, and are mainly based on theoretical estimations
of risk assessment. The following screening procedure reﬂects
the Austrian consensus [18], and is mainly based on expert
opinions. Donor screening comprises adequate history, phys-
ical examination, laboratory tests, and microbiological inves-
tigations (Table 1).
Potential donors present as healthy adults or adolescents
(optional body mass index between 17 and 35) lacking any
evidence of acute or chronic disease (e.g. autoimmune disease,
malignancy, and chronic IBDs). They should conﬁrm no
antibiotic therapy within the last 3 months, no diarrhoea
within the last 3 months, no intravenous drug abuse or other
risk behaviour for transmissible diseases, and no signiﬁcant
gastrointestinal (GI) surgery (e.g. Whipple procedure and total
colectomy). In Austria, laboratory tests comprise various
immunological and microbiological parameters, as listed in
Table 1. Since feacal transmission of cytomegalovirus infection
has not been reported, the Austrian guidelines discuss
cytomegalovirus antibodies only to be performed as an
optional screening in donors for immunocompromised
recipients, such as patients with negative cytomegalovirus
IgG antibodies and the presence of chronic IBDs, wasting
disease, or immunosuppression, including prednisolone
>20 mg daily, and a history of solid organ or stem cell
transplantation. Stool analysis for calprotectin is optional in
FMT for recurrent CDI, but is recommended in the application
of FMT for chronic IBD.
Donors repeatedly used for FMT should be retested every
6 months, and sooner in the case of certain risks for infectious
diseases (e.g. vacation in countries with a high risk for GI
infections). In cases of emergency and proposed FMT in
fulminant CDI, relatives or sexual partners may be used as
donors without the testing described above [34].
Despite or just because of the great awareness of potential
FMT-induced injury, reports about severe side effects are rare.
However, considering reported cases of successfully and safely
performed FMT in immunosuppressed patients [35], the donor
screening and infectious work-up as described above seems to
have been sufﬁcient so far.
Method
FMT can be performed either via the upper or the lower GI
tract; for both routes of application, different techniques have
been described. However, to date, there have been no
comparative methodical studies, so clinicians have to rely on
experience and expert opinions. According to empirical data,
donor faeces should be fresh, i.e. not older than 6 h, and
stored in airtight vessels at +6°C to +8°C to avoid bacterial
overgrowth.
Faecal bacteria are classiﬁed as biohazard level 2, which
requires the wearing of water-repellent garments, gloves,
facemasks, protective goggles, or shields; the use of a biological
safety cabinet is optional. Depending on faecal consistency the
entire faecal donation will be diluted with 100–500 mL of
sterile saline (0.9% NaCl) or water and homogenized in a
household blender or similar device, especially designated for
this purpose (Fig. 1a). There are, however, no standardized
data on the total weight of faeces to be used; 50–150 g seems
to be appropriate [4]. In the next step, the faecal suspension
will be ﬁltered in order to remove solid components (Fig. 1b).
Gauze pads, paper or steel ﬁlters and sieves can serve as ﬁlters
(such as are commonly used in households). Some authors
recommend coffee ﬁlters to separate faecal debris but, in our
TABLE 1. Austrian guidelines for screening stool donors
History Healthy adult or adolescent
Optionally: BMI >17 and <35
Negative for acute or chronic diseases (autoimmune
disease, IBD, malignant disease, etc.)
Negative for transmittable diseases
No antibiotics within the last 3 months
No diarrhoea within the last 3 months
Negative for intravenous drug abuse
No signiﬁcant gastrointestinal surgery (e.g. total colectomy)
Serological tests Hepatitis A antibodies (IgM), hepatitis B antigens and
antibodies (anti-HBc), hepatitis C antibodies (IgG)
HIV antigens or antibodies
Treponema pallidum haemagglutination assay
Analysis of faeces Pathogenic intestinal bacteria (Clostridium difﬁcile,
Salmonella species, Campylobacter species, EHEC,
Yersinina species, Shigella species)
Microscopic examination for ova and parasites
Giardia lamblia and Cryptosporidium antigen
Norovirus and rotavirus antigen or PCR
Calprotecin (optional in CDI; recommended for
indication IBD)
BMI, body mass index; CDI, Clostridium difﬁcile infection; CMV, cytomegalovirus;
EHEC, enterohaemorrhagic Escherichia coli; HIV, human immunodeﬁciency virus;
IBD, inﬂammatory bowel disease.
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experience, coffee ﬁlters, at least those available in Austria,
tend to clog rapidly. The objective of ﬁltration is to reﬁne the
faecal suspension by removing roughage, which might hamper
application of faeces by blocking a tube or the working channel
of the endoscope.
Depending on the route of administration, the diluted,
homogenized and ﬁltered suspension will be apportioned into
20–50-mL syringes (Fig. 1c) and administered to the patient
within the next 2 h (Fig. 1d). In our view, processing the faeces
rapidly, possibly in a closed system, is essential to protect
anaerobic bacteria from oxygen.
Recent publications reported successful transplantation of
previously frozen faecal suspension, which had specially been
prepared with glycerol [32,36,37]. These experiences are
based on small case series; therefore, we only recommend the
application of prior frozen microbiota in certain cases, such as
increased urgency or donor dropout. In such cases, faecal
samples should be stored at 80°C and gently reheated in a
37°C warm water bath over a period of 2 h [32,36,37].
Preparation of the Patient
The preparation of the patient depends on the route of
administration and on the indication for FMT.
In cases of recurrent CDI, patients receive an antibiotic
pretreatment with either vancomycin or ﬁdaxomicin for at
least 4 days in order to reduce the abundance of intestinal
C. difﬁcile. Antibiotics should be stopped 36–48 h prior to
FMT.
For application in the lower GI tract, patients receive a
conventional colon lavage, routinely given prior to colonos-
copy. As the colon lavage signiﬁcantly reduces the patient’s
microbiota [38], it is also reasonable to perform it for
administration in the upper GI tract. To extend the retention
time of the donor microbiota in the patient’s intestines,
loperamid can be provided after successful FMT; however, in
our experience, this might aggravate post-intervention side
effects, such as bloating and abdominal pain, or may lead to
nausea and emesis.
In cases of FMT via the upper GI tract, prokinetic therapy
might reduce the risk of aspiration. Also, proton-pump
inhibitors can have a positive impact on the viability of the
transplanted bacteria [34].
Route of Administration
Different routes of administration are described in the
literature. Application of faeces can be performed by colo-
noscopy to the terminal ileum and portion-wise further
downstream in the colon (Fig. 1d), or exclusively to the left
colon, via either endoscope or enema, depending on the
patient’s condition and what is available locally. Whereas 200–
500 mL of faecal suspension can be placed in the lower GI
tract [4, 14, 22], transplantation volumes in the upper GI tract
are limited, owing to the risk of aspiration. If the donor faeces
are placed in the upper GI tract, nasogastric or nasojejunal
tubes can be used; endoscopic applications via gastroscopy
have also been described. The total volume of inserted
(a) (b)
(c)
(d)
FIG. 1. (a) Dilution and homogenization
of donor faeces with 0.9% NaCl in a
blender. (b) Subsequent ﬁltration of the
homogenized and diluted faecal
suspension with a metal sieve in order to
remove debris. (c) Faecal suspension
apportioned into 20-mL syringes prior to
application. (d) Introduction of faecal
suspension into the working channel of a
colonoscope for faecal microbiota
transplantation into the lower
gastrointestinal tract.
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bacterial suspension is usually much lower, approximately 25–
50 mL [39], but transplanted volumes of up to 500 mL via
nasojejunal tubes (2–3 min/50 mL) have also been reported
[15]. Nasoduodenal application has been used in the only
randomized controlled study [15].
Physicians must be aware of increasing risks of severe side
effects according to transplantation volumes in the upper GI
tract. Given a recently published case of pneumoperitoneum
and septic shock with a lethal outcome after FMT via a
nasojejunal tube [40], we highly recommend conﬁrmation of
the correct tube position by X-ray before donor faeces are
installed in the upper GI tract [41].
The authors of this review deﬁnitely recommend the lower
GI tract as the preferable route of administration, for safety
reasons and because of the larger transplantable volume.
Cases of severe CDI with paralytic ileus, and patients receiving
immunosuppressive therapy, have also been successfully
treated with FMT by colonoscopy, without any serious
infectious side events [28,35,42]. A recently published review
revealed a non-signiﬁcant advantage of FMT for recurrent CDI
via colonoscopy over FMT in the upper GI tract via nasogastric
or jejunal tubes (91.4% vs. 82.3%) [33].
The route of administration has to be chosen according to
the phenotype of the disease and comorbidities of the patient,
and remains an individualized decision. However, given the
risks and beneﬁts, FMT via colonoscopy seems to be effective
and safe, and in the authors’ view is therefore the preferable
route of administration.
Conclusion
FMT is a new treatment option for patients with dysbio-
sis-induced diseases [2–8], and for patients with recurrent
CDI. Because of the lack of treatment alternatives for some
of these patients, we believe that FMT is a major improve-
ment in the therapeutic arsenal for physicians. We also
believe that too strict regulations for FMT from medical
authorities would prevent this form of therapy for many
patients who could beneﬁt. Furthermore, this would displace
this method to an alternative medicine sector, resulting in
even more potential safety risks for patients. Scientiﬁc
societies in other counties are therefore called on to develop
FMT guidelines that are practicable for most physicians in this
ﬁeld.
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